Ads
related to: primary myelofibrosis treatment
Search results
Results from the WOW.Com Content Network
Primary myelofibrosis (PMF) is a rare bone marrow blood cancer. [1] ... Other treatment options are largely supportive, and do not alter the course of the disorder ...
Prefibrotic primary myelofibrosis (Pre-PMF) is a rare blood cancer, classified by the World Health Organization as a distinct type of myeloproliferative neoplasm in 2016. [1] The disease is progressive to overt primary myelofibrosis , though the rate of progression is variable and not all patients progress.
In the European Union, fedratinib is indicated for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, following polycythaemia vera or essential thrombocythaemia, who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. [3]
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
Essential thrombocythaemia, essential thrombocytosis, primary thrombocytosis: Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia. Specialty: Hematology Symptoms: Fatigue, insomnia, migraines, headache, and dizziness. [1] Complications
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. [1] [2] It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3). Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs. [2]
Ads
related to: primary myelofibrosis treatment